←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Peptide Drug Conjugate
Raphael Clynes
MD, PhD
🏢Xencor🌐USA
Chief Medical Officer
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Raphael Clynes is a leader in antibody engineering and conjugate therapies and has advanced bispecific antibody and peptide-drug conjugate concepts. He has held senior roles at Bristol Myers Squibb and Xencor in oncology drug development. His work bridges Fc biology and conjugate design for cancer treatment.
Share:
🧪Research Fields 研究领域
antibody drug conjugates
Fc engineering
bispecific antibodies
cancer immunotherapy
peptide conjugate design
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Raphael Clynes 的研究动态
Follow Raphael Clynes's research updates
留下邮箱，当我们发布与 Raphael Clynes（Xencor）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment